{"id":"W3198880734","doi":"10.1038/s41408-021-00544-x","title":"A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences North","funders":"Singapore General Hospital; National University of Singapore; Onyx Pharmaceuticals; Duke-NUS Medical School","keywords":"Carfilzomib; Dexamethasone; Medicine; Cyclophosphamide; Internal medicine; Phase (matter); Oncology; Intensive care medicine; Chemotherapy; Lenalidomide; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009325151,0.0005108969,0.001127319,0.0002025317,0.0004732413,0.0008618446,0.0006625301,0.003014164,0.004450953],"category_scores_gemma":[0.001159816,0.0002417845,0.0006061303,0.0002541428,0.000364478,0.0005412808,0.0002386989,0.003983818,0.00128925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001289598,"about_ca_system_score_gemma":0.0008803718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001207493,"about_ca_topic_score_gemma":0.00455503,"domain_scores_codex":[0.999712,0.0001233903,0.00001724632,0.00004615764,0.00004316544,0.00005796249],"domain_scores_gemma":[0.9993026,0.0002051169,0.00005722018,0.00002363044,0.00004944377,0.0003620285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2233808,0.01939122,0.0112291,0.0009343246,0.0008961449,0.006653289,0.0004820919,0.002067262,0.02011033,0.001922524,0.2105362,0.5023968],"study_design_scores_gemma":[0.4862376,0.2004672,0.04293446,0.0003519593,0.0009479629,0.009100086,0.0003047311,0.005406641,0.006029191,0.004266497,0.2438518,0.0001019483],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7568472,0.03056332,0.002093171,0.1566262,0.01172158,0.003372921,0.005268047,0.0004287618,0.03307881],"genre_scores_gemma":[0.8704304,0.00930238,0.004184124,0.08039477,0.004498162,0.002139495,0.004126606,0.00007704108,0.0248471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004450953,"threshold_uncertainty_score":0.0148899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02598774815005948,"score_gpt":0.3327062772657641,"score_spread":0.3067185291157046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}